Treating certain bacterial infections. It may be used in combination with other medicines to treat acne or certain amoeba infections. It may be used to prevent certain types of malaria in travelers who will be visiting malaria-infected areas for less than 4 months. It may also be used to prevent or slow the progression of anthrax after exposure.
Doxycycline Hawon delayed-release capsules is a tetracycline antibiotic. It works by slowing the growth of bacteria. Slowing the bacteria's growth allows the body's immune system to destroy the bacteria.
Doxycycline Hawon indications
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored
To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hawon Tablets, USP and other antibacterial drugs, Doxycycline Hawon Tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Treatment
Doxycycline is indicated for the treatment of the following infections:
•
Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae.
•
Respiratory tract infections caused by Mycoplasma pneumoniae.
•
Lymphogranuloma venereum caused by Chlamydia trachomatis.
•
Psittacosis (ornithosis) caused by Chlamydophila psittaci.
•
Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence.
•
Inclusion conjunctivitis caused by Chlamydia trachomatis.
•
Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis.
•
Nongonococcal urethritis caused by Ureaplasma urealyticum.
•
Relapsing fever due to Borrelia recurrentis.
Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms:
•
Chancroid caused by Haemophilus ducreyi.
•
Plague due to Yersinia pestis.
•
Tularemia due to Francisella tularensis.
•
Cholera caused by Vibrio cholerae.
•
Campylobacter fetus infections caused by Campylobacter fetus.
•
Brucellosis due to Brucella species (in conjunction with streptomycin).
•
Bartonellosis due to Bartonella bacilliformis.
•
Granuloma inguinale caused by Klebsiella granulomatis.
Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended.
Doxycycline is indicated for treatment of infections caused by the following gram-negative bacteria, when bacteriologic testing indicates appropriate susceptibility to the drug:
•
Escherichia coli.
•
Enterobacter aerogenes.
•
Shigella species.
•
Acinetobacter species.
•
Respiratory tract infections caused by Haemophilus influenzae.
•
Respiratory tract and urinary tract infections caused by Klebsiella species.
Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug:
•
Upper respiratory infections caused by Streptococcus pneumoniae.
•
Anthrax due to Bacillus anthracis, including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis.
When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections:
•
Uncomplicated gonorrhea caused by Neisseria gonorrhoeae.
•
Syphilis caused by Treponema pallidum.
•
Yaws caused by Treponema pallidum subspecies pertenue.
•
Listeriosis due to Listeria monocytogenes.
•
Vincent’s infection caused by Fusobacterium fusiforme.
•
Actinomycosis caused by Actinomyces israelii.
•
Infections caused by Clostridium species.
In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides.
In severe acne, doxycycline may be useful adjunctive therapy.
Prophylaxis
Doxycycline is indicated for the prophylaxis of malaria due to Plasmodium falciparum in short-term travelers (<4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains.
How should I use Doxycycline Hawon?
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
Use Doxycycline Hawon delayed-release tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Take Doxycycline Hawon delayed-release tablets by mouth with or without food. If stomach upset occurs, take with food or milk to reduce stomach irritation.
Swallow Doxycycline Hawon delayed-release tablets whole. Do not crush or chew before swallowing.
Drink plenty of fluids with Doxycycline Hawon delayed-release tablets to wash it down. This will also help to decrease the risk of throat irritation from Doxycycline Hawon delayed-release tablets.
If you have trouble swallowing Doxycycline Hawon delayed-release tablets whole, you may carefully break up the tablet and sprinkle it on a spoonful of smooth applesauce. Do not crush or damage the beads in this tablet. Do not use hot applesauce. Mix the medicine with the applesauce and swallow the mixture right away, followed by a glass of water. Do not chew the mixture. Do not store the mixture for use at a later time.
Do not take an antacid that has aluminum, calcium, or magnesium in it; bismuth-containing products; urinary alkalinizers (eg, sodium bicarbonate); or multivitamins with minerals within 2 hours before or after you take Doxycycline Hawon delayed-release tablets.
To clear up your infection completely, take Doxycycline Hawon delayed-release tablets for the full course of treatment. Keep taking it even if you feel better in a few days.
If you are taking Doxycycline Hawon delayed-release tablets to prevent malaria, you should begin to take it 1 to 2 days before you travel to the malaria-infected area. You will need to keep taking it for 4 weeks after you leave the area. Discuss any questions with your doctor.
Do not use Doxycycline Hawon delayed-release tablets if it is outdated or has been stored incorrectly.
If you miss a dose of Doxycycline Hawon delayed-release tablets, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Doxycycline Hawon delayed-release tablets.
Doxycycline Hawon dosage
sponsored
Usual Dosage And Administration
The usual dosage and frequency of administration of doxycycline differs from that of the other tetracyclines. Exceeding the recommended dosage may result in an increased incidence of side effects.
Adults
The usual dose of oral doxycycline is 200 mg on the first day of treatment (administered 100 mg every 12 hours), followed by a maintenance dose of 100 mg daily.
The maintenance dose may be administered as a single dose or as 50 mg every 12 hours. In the management of more severe infections (particularly chronic infections of the urinary tract), 100 mg every 12 hours is recommended.
Pediatric Patients
For all pediatric patients weighing less than 45 kg with severe or life threatening infections (e.g., anthrax, Rocky Mountain spotted fever), the recommended dosage of doxycycline is 2.2 mg per kg of body weight administered every 12 hours. Pediatric patients weighing 45 kg or more should receive the adult dose.
For pediatric patients with less severe disease (greater than 8 years of age and weighing less than 45 kg), the recommended dosage schedule of doxycycline is 4.4 mg per kg of body weight divided into two doses on the first day of treatment, followed by a maintenance dose of 2.2 mg per kg of body weight (given as a single daily dose or divided into twice daily doses). For pediatric patients weighing over 45 kg, the usual adult dose should be used.
Administration of adequate amounts of fluid along with capsule and tablet forms of drugs in the tetracycline-class is recommended to wash down the drugs and reduce the risk of esophageal irritation and ulceration.
If gastric irritation occurs, doxycycline may be given with food or milk.
When used in streptococcal infections, therapy should be continued for 10 days.
Uncomplicated urethral, endocervical, or rectal infection caused by Chlamydia trachomatis: 100 mg by mouth twice a day for 7 days. As an alternate dosing regimen for uncomplicated urethral or endocervical infection caused by Chlamydia trachomatis, administer 200 mg by mouth once-a-day for 7 days.
Uncomplicated gonococcal infections in adults (except anorectal infections in men): 100 mg, by mouth, twice-a-day for 7 days. As an alternate single visit dose, administer 300 mg stat followed in one hour by a second 300 mg dose.
Nongonococcal urethritis (NGU) caused by U. urealyticum: 100 mg by mouth twice-aday for 7 days.
Syphilis – early: Patients who are allergic to penicillin should be treated with doxycycline 100 mg by mouth twice-a-day for 2 weeks.
Syphilis of more than one year's duration: Patients who are allergic to penicillin should be treated with doxycycline 100 mg by mouth twice-a-day for 4 weeks.
Acute epididymo-orchitis caused by C. trachomatis: 100 mg, by mouth, twice-a-day for at least 10 days.
For Prophylaxis Of Malaria
For adults, the recommended dose is 100 mg daily. For children over 8 years of age, the recommended dose is 2 mg/kg given once daily up to the adult dose. Prophylaxis should begin 1 or 2 days before travel to the malarious area. Prophylaxis should be continued daily during travel in the malarious area and for 4 weeks after the traveler leaves the malarious area.
Inhalational Anthrax (post-exposure)
Adults: 100 mg, of doxycycline, by mouth, twice-a-day for 60 days. Children: weighing less than 45 kg, 2.2 mg/kg of body weight, by mouth, twice-a-day for 60 days. Children weighing 45 kg or more should receive the adult dose.
Sprinkling The Tablet Over Applesauce
Doxycycline Hawon Delayed-Release Tablets may also be administered by carefully breaking up the tablet and sprinkling the tablet contents (delayed-release pellets) on a spoonful of applesauce. The delayed-release pellets must not be crushed or damaged when breaking up the tablet. Any loss of pellets in the transfer would prevent using the dose. The applesauce/Doxycycline Hawon Delayed-Release Tablets mixture should be swallowed immediately without chewing and may be followed by a glass of water if desired. The applesauce should not be hot, and it should be soft enough to be swallowed without chewing. In the event that a prepared dose of applesauce/Doxycycline Hawon Delayed-Release Tablets cannot be taken immediately, the mixture should be discarded and not stored for later use.
How supplied
Dosage Forms And Strengths
Doxycycline Hawon Delayed-Release Tablets, 75 mg are white, oval, scored tablets containing yellow pellets and debossed with “D|5” on one face and plain on the other. Each tablet contains specially coated pellets of Doxycycline Hawon equivalent to 75 mg of doxycycline.
Doxycycline Hawon Delayed-Release Tablets, 100 mg are white, oval, scored tablets containing yellow pellets and debossed with “D|0” on one face and plain on the other. Each tablet contains specially coated pellets of Doxycycline Hawon equivalent to 100 mg of doxycycline.
Doxycycline Hawon Delayed-Release Tablets, 150 mg are white, rectangular, dual scored tablets containing yellow pellets and debossed with “D|I|I” on one face and plain on the other. Each tablet contains specially coated pellets of Doxycycline Hawon equivalent to 150 mg of doxycycline.
Doxycycline Hawon Delayed-Release Tablets, 200 mg are white, oval, scored tablets containing yellow pellets and debossed with “D|D” on one face and plain on the other. Each tablet contains specially coated pellets of Doxycycline Hawon equivalent to 200 mg of doxycycline.
Storage And Handling
Doxycycline Hawon Delayed-Release Tablets, 75 mg are white, oval, scored tablets containing yellow pellets and debossed with “D|5” on one face and plain on the other. Each tablet contains specially coated pellets of Doxycycline Hawon equivalent to 75 mg of doxycycline.
Bottles of 60 tablets NDC 68308-775-60
Doxycycline Hawon Delayed-Release Tablets, 100 mg are white, oval, scored tablets containing yellow pellets and debossed with “D|0” on one face and plain on the other. Each tablet contains specially coated pellets of Doxycycline Hawon equivalent to 100 mg of doxycycline.
Bottles of 100 tablets NDC 68308-710-10
Doxycycline Hawon Delayed-Release Tablets, 150 mg are white, rectangular, dual scored tablets containing yellow pellets and debossed with “D|I|I” on one face and plain on the other. Each tablet contains specially coated pellets of Doxycycline Hawon equivalent to 150 mg of doxycycline.
Bottles of 100 tablets NDC 68308-715-10
Doxycycline Hawon Delayed-Release Tablets, 200 mg are white, oval, scored tablets containing yellow pellets and debossed with “D|D” on one face and plain on the other. Each tablet contains specially coated pellets of Doxycycline Hawon equivalent to 200 mg of doxycycline.
Bottles of 60 tablets NDC 68308-716-60
Store at 25° C (77° F); excursions permitted to 15 – 30° C (59 – 86° F). Dispense in a tight, light-resistant container (USP).
Medications containing metal ions (antacids, products containing iron, magnesium, calcium) form inactive chelates with doxycycline, in connection with what it is necessary to avoid their simultaneous use.
It needed to avoid combination with penicillins, cephalosporins, bactericidal action and is an antagonist of bacteriostatic antibiotics (including doxycycline).
Absorption of doxycycline is reduced by cholestyramine and colestipol (observe the interval between the reception of at least 3 h).
Due to suppression of intestinal microflora doxycycline reduces prothrombin index which requires dose adjustment of indirect anticoagulants.
Doxycycline Hawon reduces the reliability of contraception and increases the frequency of breakthrough bleeding while taking estrogen-containing oral contraceptives.
Simultaneous administration of Doxycycline Hawon with:
barbiturates, carbamazepine, phenytoin concentrations of doxycycline in plasma decreases due to the induction of liver enzymes, which may be responsible for the decrease of its antibacterial action.
The safety and efficacy of Doxycycline Hawon delayed-release tablets, 200 mg as a single daily dose was evaluated in a multicenter, randomized, double-blind, active-controlled study. Doxycycline Hawon delayed-release tablets, 200 mg was given orally once-a-day for 7 days and compared to Doxycycline Hawon capsules 100 mg given orally twice daily for 7 days for the treatment of men and women with uncomplicated urogenital C. trachomatis infection.
Adverse events in the Safety Population were reported by 99 (40.2%) subjects in the Doxycycline Hawon delayed-release tablets, 200 mg treatment group and 132 (53.2%) subjects in the Doxycycline Hawon capsules reference treatment group. Most AEs were mild in intensity. The most commonly reported adverse events in both treatment groups were nausea, vomiting, diarrhea, and bacterial vaginitis, Table 1.
Table 1: Adverse Reactions Reported in Greater than or Equal to 2% of Subjects
Doxycycline Hawon delayed-release tablets, 200 mg
N = 246
Preferred Term
n (%)
Subjects with any AE
99 (40.2)
Nausea
33 (13.4)
Vomiting
20 (8.1)
Headache
5 (2.0)
Diarrhea
8 (3.3)
Abdominal Pain Upper
5 (2.0)
Vaginitis Bacterial
8 (3.3)
Vulvovaginal Mycotic Infection
5 (2.0)
Because clinical trials are conducted under prescribed conditions, adverse reaction rates observed in the clinical trial may not always reflect the rates observed in practice.
Postmarketing Experience
The following adverse reactions have been identified during post-approval use of doxycycline. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate a causal relationship to drug exposure.
Due to oral doxycycline's virtually complete absorption, side effects to the lower bowel, particularly diarrhea, have been infrequent. The following adverse reactions have been observed in patients receiving tetracyclines:
Gastrointestinal: Anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, and inflammatory lesions (with monilial overgrowth) in the anogenital region. Hepatotoxicity has been reported. These reactions have been caused by both the oral and parenteral administration of tetracyclines. Esophagitis and esophageal ulcerations have been reported in patients receiving capsule and tablet forms of drugs in the tetracycline- class. Most of these patients took medications immediately before going to bed.
Skin: Maculopapular and erythematous rashes, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, and erythema multiforme have been reported. Photosensitivity is discussed above.
Renal: Rise in BUN has been reported and is apparently dose-related.
Hypersensitivity reactions: Urticaria, angioneurotic edema, anaphylaxis, anaphylactoid purpura, serum sickness, pericarditis, and exacerbation of systemic lupus erythematosus.
Blood: Hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia have been reported.
Intracranial Hypertension: Intracranial hypertension (IH, pseudotumor cerebri) has been associated with the use of tetracycline
Thyroid Gland Changes: When given over prolonged periods, tetracyclines have been reported to produce brown-black microscopic discoloration of thyroid glands. No abnormalities of thyroid function are known to occur.
Use in pregnancy & lactation: Use is not recommended during the last half of pregnancy and nursing mother.
Use in children: Use in children <8 years is not recommended as tetracyclines may cause permanent discoloration of the teeth, enamel hypoplasia and inhibition of linear skeletal growth.
The results of a survey conducted on ndrugs.com for Doxycycline Hawon are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Doxycycline Hawon. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
User reports
Consumer reported useful
No survey data has been collected yet
Consumer reported price estimates
No survey data has been collected yet
Consumer reported time for results
No survey data has been collected yet
Consumer reported age
No survey data has been collected yet
Consumer reviews
There are no reviews yet. Be the first to write one!
